Drugs / l-LV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01836653 Background | May 2013 → Mar 2017 | metastasis from malignant tumor of colon | EPS Corporation | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | l-LV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01836653 ↗ |
| Route | Intravenous | “200 mg/m2 intravenously administered over 120 minutes” NCT01836653 ↗ |